Literature DB >> 12921317

Pertussis vaccine controversies and acellular pertussis vaccine.

Raju C Shah1, Anuj R Shah.   

Abstract

Pertussis still continues to cause significant morbidity and mortality worldwide. Because of the high reactogenicity of whole cell pertussis vaccine, it had evoked public controversy in several countries. In 1970 Japan abandoned use of whole cell pertussis vaccine and mounted efforts to develop better vaccine. To date, nearly 24 acellular pertussis vaccines have been developed, using different number and quantity of components. No acellular vaccine is most or least immunogenic with respect to all included antigens. Vaccine efficacy and duration of immunity is comparable with whole cell pertussis vaccine. The adverse events are two thirds less compared to whole cell vaccine.

Mesh:

Substances:

Year:  2003        PMID: 12921317     DOI: 10.1007/bf02723139

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  10 in total

1.  A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Authors:  M E Pichichero; M A Deloria; M B Rennels; E L Anderson; K M Edwards; M D Decker; J A Englund; M C Steinhoff; A Deforest; B D Meade
Journal:  Pediatrics       Date:  1997-11       Impact factor: 7.124

2.  Developments in pertussis immunisation in Japan.

Authors:  M Kimura; H Kuno-Sakai
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

3.  Recommended childhood immunization schedule--United States, 1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-01-15       Impact factor: 17.586

4.  Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.

Authors:  M E Pichichero; K M Edwards; E L Anderson; M B Rennels; J A Englund; D E Yerg; W C Blackwelder; D L Jansen; B D Meade
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

5.  Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.

Authors:  C M Morgan; D A Blumberg; J D Cherry; K S Reisinger; M M Blatter; J L Blumer; C L Dekker; M G Stout; P D Christenson
Journal:  Am J Dis Child       Date:  1990-01

6.  Comparison of 13 acellular pertussis vaccines: overview and serologic response.

Authors:  K M Edwards; B D Meade; M D Decker; G F Reed; M B Rennels; M C Steinhoff; E L Anderson; J A Englund; M E Pichichero; M A Deloria
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

7.  Comparison of 13 acellular pertussis vaccines: adverse reactions.

Authors:  M D Decker; K M Edwards; M C Steinhoff; M B Rennels; M E Pichichero; J A Englund; E L Anderson; M A Deloria; G F Reed
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

8.  Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-03-28

9.  Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.

Authors:  P Olin; F Rasmussen; L Gustafsson; H O Hallander; H Heijbel
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

10.  Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups.

Authors:  J D Cherry; E A Mortimer; J G Hackell; J V Scott
Journal:  Dev Biol Stand       Date:  1991
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.